首页|基于组分中药理论的薏苡仁-知母药对治疗糖尿病患者的配伍特点

基于组分中药理论的薏苡仁-知母药对治疗糖尿病患者的配伍特点

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
药对是源于中医传统经方或验方,依据中药配伍原则,能长期应用并指导临床实践的两味药物相对固定的配伍形式,具有协同增效或配伍减毒的作用.薏苡仁-知母为典型的清热滋阴药对,二者相辅相成,治疗阴虚热盛型糖尿病患者效果显著.其成分知母皂苷、知母多糖、芒果苷、薏苡仁多糖等对糖尿病均有较好的干预作用.现从中医理论及现代药理学研究等层面探究薏苡仁-知母药对治疗糖尿病的配伍特点,剖析主要活性成分的降糖作用和作用机制,为治疗糖尿病的新药研究提供理论基础.
Compatibility Characteristics of Coicis Semen-Anemarrhenae Rhizoma Drug Pair in the Treatment of Diabetes in Patients Based on the Theory of Chinese Medicine Components
Drug pair,originating from traditional Chinese medicine(TCM)classical formulas or empirical prescriptions,refers to a relatively fixed combination of two herbal drugs based on the principles of Chinese medicine compatibility.These combinations can be consistently applied and guide clinical practice,often enhancing efficacy or reducing toxicity through synergistic effects.Coicis Semen-Anemarrhenae Rhizoma is a typical drug pair known for its heat-clearing and yin-nourishing properties.They complement each other and have shown significant effectiveness in treating diabetes characterized by yin deficiency and exuberant heat.The ac-tive components,such as timosaponin,Anemarrhena asphodeloides polysaccharides,mangiferin,and coixanfrom,have demonstrated beneficial effects on diabetes.This paper explored the compatibility characteristics of Coicis Semen-Anemarrhenae Rhizoma drug pair in treating diabetes from both TCM theory and modern pharmacological research and analyzed the hypoglycemic effects and mechanisms of action of the main active components,providing a theoretical foundation for the new drug development for diabetes.

Chinese medicine componentCoicis SemenAnemarrhenae RhizomaDrug pairDiabetes

陆益平、刘远洋、叶嘉焕、苏琳祺、唐素梅、傅鹏、韦建华、唐慧勤

展开 >

广西中医药大学,广西高校中药神经-代谢及免疫药理重点实验室,南宁,530000

广西壮瑶药重点实验室,南宁,530000

组分中药 薏苡仁 知母 药对 糖尿病

国家重点研发计划项目广西高校中青年教师基础能力提升项目中药学广西一流学科建设项目广西中医药大学项目广西中医药大学项目广西中医药大学项目广西中医药大学项目广西中医药大学项目广西壮瑶药重点实验室建设项目第八批广西壮族自治区特聘专家项目广西研究生联合培养基地项目

2019YFC1712304KY2016YB215桂教科研[2022]1号ZYX2017009YSL170012021MS002桂中医大科[2022]4号桂中医大科[2022]3号桂科基字[2014]32号桂人才通字[2019]13号桂学位[2021]6号

2024

10.3969/j.issn.1673-7202.2024.09.020

世界中医药
世界中医药学会联合会

世界中医药

CSTPCDCHSSCD北大核心
影响因子：1.266
ISSN：1673-7202
年,卷(期)：2024.19(9)